NRx Pharmaceuticals Archives - Page 3 of 5

Jan. 5, 2023

NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference

NRx Pharmaceuticals, Inc. today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates.

Jan. 3, 2023

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality – First Clinical Site Contracted

NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.

Dec. 20, 2022

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Close of Definitive Settlement Agreements

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. today announced the close of the definitive settlement agreements to resolve the pending litigation between Relief and NRx Pharmaceuticals’ wholly owned subsidiary, NeuroRx, Inc.

Dec. 5, 2022

NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

NRx Pharmaceuticals today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs. She will lead the Company’s clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director.

NRx Receives Nasdaq Notice of Listing Compliance

NRx Pharmaceuticals today announced it received written notice on December 1, 2022 from The Nasdaq Stock Market informing NRx Pharmaceuticals that it has regained compliance with the minimum bid price requirement under the Nasdaq Listing Rule 5450(a)(1) (which requires the Company to maintain a minimum closing bid price of $1.00 per share) and the matter is now closed.

Nov. 14, 2022

NRx Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

NRx Pharmaceuticals, Inc. today announced its financial results for the third quarter of 2022 and provided a business and clinical update.

Nov. 13, 2022

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. Announce Execution of Definitive Settlement Agreements

Relief Therapeutics Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTD) (“Relief”), and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (“NRx Pharmaceuticals”), today announced that they have entered into definitive settlement agreements to resolve their pending litigation.

Nov. 10, 2022

NRx Pharmaceuticals to Report Third Quarter 2022 Results on November 14, 2022

NRx Pharmaceuticals, Inc. today announced that management will report third quarter 2022 financial results prior to the market open on November 14, 2022.

Nov. 9, 2022

NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. today announced the release of the first batches manufactured in the U.S. of NRX-101, its Phase 3-ready investigational drug, targeting suicidal bipolar depression and with future study plans for post-traumatic stress disorder (PTSD).

Cookie	Duration	Description
_wpfuuid	11 years	This cookie is used by the WPForms WordPress plugin. The cookie is used to allows the paid version of the plugin to connect entries by the same user and is used for some additional features like the Form Abandonment addon.
cookielawinfo-checkbox-advertisement	1 year	Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
nlbi_1816097	session	A load balancing cookie set to ensure requests by a client are sent to the same origin server.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
visid_incap_1816097	1 year	SiteLock sets this cookie to provide cloud-based website security services.

Cookie	Duration	Description
_jsuid	1 year	This cookie contains random number which is generated when a visitor visits the website for the first time. This cookie is used to identify the new visitors to the website.
cluid	1 year	This cookie is used for websites which is having multiple domains to identify the same visitor across multiple domains.
CONSENT	2 years	YouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
mo_has_visited	11 years	This cookie is used for setting an unique ID for the visitor which helps to get the accurate number of specific visitor on the website.
mo_is_new	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.
mo_page_views_counter	session	This cookie is used for counting the new visitors to the website by assigning a unique visitor ID.

Cookie	Duration	Description
c	6 months 2 days	This cookie is set by Rubicon Project to control synchronization of user identification and exchange of user data between various ad services.
uuid	1 year 27 days	MediaMath sets this cookie to avoid the same ads from being shown repeatedly and for relevant advertising.
VISITOR_INFO1_LIVE	5 months 27 days	A cookie set by YouTube to measure bandwidth that determines whether the user gets the new or old player interface.
YSC	session	YSC cookie is set by Youtube and is used to track the views of embedded videos on Youtube pages.
yt-remote-connected-devices	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.
yt-remote-device-id	never	YouTube sets this cookie to store the video preferences of the user using embedded YouTube video.

Cookie	Duration	Description
incap_ses_1371_1816097	session	No description
unpoco_101344884	1 day	No description